L-ASPARAGINASE 10000 IU - search results

United States - English - NLM (National Library of Medicine)

oncaspar- pegaspargase injection, solution

baxalta us inc. - pegaspargase (unii: 7d96ir0ppm) (pegaspargase - unii:7d96ir0ppm) - pegaspargase 750 [iu] in 1 ml - oncaspar® is indicated as a component of a multi-agent chemotherapeutic regimen for the first-line treatment of pediatric and adult patients with all. oncaspar is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of pediatric and adult patients with all and hypersensitivity to native forms of l-asparaginase. oncaspar is contraindicated in patients with a: - history of serious hypersensitivity reactions, including anaphylaxis, to oncaspar or to any of the excipients [see warnings and precautions (5.1)] . - history of serious thrombosis with prior l-asparaginase therapy [see warnings and precautions (5.2)] . - history of pancreatitis, including pancreatitis related to prior l-asparaginase therapy [see warnings and precautions (5.3)] . - history of serious hemorrhagic events with prior l-asparaginase therapy [see warnings and precautions (5.5)] . - severe hepatic impairment [see warnings and precautions (5.6)] . risk summary there are no available data on the use of oncaspar i

Israel - English - Ministry of Health

kidrolase

cts ltd - asparaginase - powder for solution for injection - asparaginase 10000 iu/vial - asparaginase - asparaginase - acute lymphoblastic leukemia, acute myeloblastic leukemia.

New Zealand - English - Medsafe (Medicines Safety Authority)

leunase

sanofi-aventis new zealand limited - asparaginase 10000 [iu] (derived from cultures of e.coli hap ex japan, expressed as 10,000ku) - powder for injection - 10,000ku - active: asparaginase 10000 [iu] (derived from cultures of e.coli hap ex japan, expressed as 10,000ku) - treatment of acute lymphoblastic leukaemia